Cargando…

Role of Nebulized Heparin in Clinical Outcome of COVID-19 Patients with Respiratory Symptoms: A Systematic Review

Coronavirus disease-2019 (COVID-19) is an extremely contagious illness caused by the SARS-CoV-2 virus and has been declared a pandemic by the World Health Organization (WHO). There are currently no particular treatments, however, nebulized heparin has been offered as a viable therapy. The purpose of...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Bhavna, Ahluwalia, Pallavi, Gupta, Nidhi, Gupta, Anish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Jaypee Brothers Medical Publishers 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452767/
https://www.ncbi.nlm.nih.gov/pubmed/37636853
http://dx.doi.org/10.5005/jp-journals-10071-24511
_version_ 1785095753500196864
author Gupta, Bhavna
Ahluwalia, Pallavi
Gupta, Nidhi
Gupta, Anish
author_facet Gupta, Bhavna
Ahluwalia, Pallavi
Gupta, Nidhi
Gupta, Anish
author_sort Gupta, Bhavna
collection PubMed
description Coronavirus disease-2019 (COVID-19) is an extremely contagious illness caused by the SARS-CoV-2 virus and has been declared a pandemic by the World Health Organization (WHO). There are currently no particular treatments, however, nebulized heparin has been offered as a viable therapy. The purpose of this systematic review is to assess the efficacy of nebulized heparin in COVID-19 patients with respiratory symptoms. METHODS: Relevant studies were identified through a systematic search of the PubMed, Medline, Embase, Cochrane Library and Web of Science, and Scopus databases. The search terms included “nebulized heparin,” “COVID-19,” and “SARS-CoV-2.” Studies that evaluated the use of nebulized heparin in COVID-19 patients with respiratory symptoms were included. The rest of the studies along with those that were not published in English were excluded. The systematic review was registered under PROSPERO-CRD42023413927. OBSERVATIONS: Five studies have been included in this systematic review. Case reports, case series, observational studies, and randomized controlled trial (RCT) comprised the studies. The patient sample sizes ranged from 2 to 98. The studies assessed the efficacy of nebulized heparin in COVID-19 patients with variable disease severity. The evaluated outcomes included mortality, hospital stay duration, oxygen requirements, and laboratory parameters. CONCLUSION: Based on the clinical studies included in this systematic review, nebulized heparin may be useful in the management of COVID-19. Oxygen saturation was greater, inflammatory indicators were lower, and hospital stays were shorter in these patients. However, the studies had limitations, including inconsistent sample sizes, varying dosages of nebulized heparin, and no control groups. Nebulized heparin in patients with COVID-19 needs to be studied further to determine its safety and effectiveness. HOW TO CITE THIS ARTICLE: Gupta B, Ahluwalia P, Gupta N, Gupta A. Role of Nebulized Heparin in Clinical Outcome of COVID-19 Patients with Respiratory Symptoms: A Systematic Review. Indian J Crit Care Med 2023;27(8):572–579.
format Online
Article
Text
id pubmed-10452767
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Jaypee Brothers Medical Publishers
record_format MEDLINE/PubMed
spelling pubmed-104527672023-08-26 Role of Nebulized Heparin in Clinical Outcome of COVID-19 Patients with Respiratory Symptoms: A Systematic Review Gupta, Bhavna Ahluwalia, Pallavi Gupta, Nidhi Gupta, Anish Indian J Crit Care Med Systematic Review Coronavirus disease-2019 (COVID-19) is an extremely contagious illness caused by the SARS-CoV-2 virus and has been declared a pandemic by the World Health Organization (WHO). There are currently no particular treatments, however, nebulized heparin has been offered as a viable therapy. The purpose of this systematic review is to assess the efficacy of nebulized heparin in COVID-19 patients with respiratory symptoms. METHODS: Relevant studies were identified through a systematic search of the PubMed, Medline, Embase, Cochrane Library and Web of Science, and Scopus databases. The search terms included “nebulized heparin,” “COVID-19,” and “SARS-CoV-2.” Studies that evaluated the use of nebulized heparin in COVID-19 patients with respiratory symptoms were included. The rest of the studies along with those that were not published in English were excluded. The systematic review was registered under PROSPERO-CRD42023413927. OBSERVATIONS: Five studies have been included in this systematic review. Case reports, case series, observational studies, and randomized controlled trial (RCT) comprised the studies. The patient sample sizes ranged from 2 to 98. The studies assessed the efficacy of nebulized heparin in COVID-19 patients with variable disease severity. The evaluated outcomes included mortality, hospital stay duration, oxygen requirements, and laboratory parameters. CONCLUSION: Based on the clinical studies included in this systematic review, nebulized heparin may be useful in the management of COVID-19. Oxygen saturation was greater, inflammatory indicators were lower, and hospital stays were shorter in these patients. However, the studies had limitations, including inconsistent sample sizes, varying dosages of nebulized heparin, and no control groups. Nebulized heparin in patients with COVID-19 needs to be studied further to determine its safety and effectiveness. HOW TO CITE THIS ARTICLE: Gupta B, Ahluwalia P, Gupta N, Gupta A. Role of Nebulized Heparin in Clinical Outcome of COVID-19 Patients with Respiratory Symptoms: A Systematic Review. Indian J Crit Care Med 2023;27(8):572–579. Jaypee Brothers Medical Publishers 2023-08 /pmc/articles/PMC10452767/ /pubmed/37636853 http://dx.doi.org/10.5005/jp-journals-10071-24511 Text en Copyright © 2023; The Author(s). https://creativecommons.org/licenses/by-nc/4.0/© The Author(s). 2023 Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and non-commercial reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated.
spellingShingle Systematic Review
Gupta, Bhavna
Ahluwalia, Pallavi
Gupta, Nidhi
Gupta, Anish
Role of Nebulized Heparin in Clinical Outcome of COVID-19 Patients with Respiratory Symptoms: A Systematic Review
title Role of Nebulized Heparin in Clinical Outcome of COVID-19 Patients with Respiratory Symptoms: A Systematic Review
title_full Role of Nebulized Heparin in Clinical Outcome of COVID-19 Patients with Respiratory Symptoms: A Systematic Review
title_fullStr Role of Nebulized Heparin in Clinical Outcome of COVID-19 Patients with Respiratory Symptoms: A Systematic Review
title_full_unstemmed Role of Nebulized Heparin in Clinical Outcome of COVID-19 Patients with Respiratory Symptoms: A Systematic Review
title_short Role of Nebulized Heparin in Clinical Outcome of COVID-19 Patients with Respiratory Symptoms: A Systematic Review
title_sort role of nebulized heparin in clinical outcome of covid-19 patients with respiratory symptoms: a systematic review
topic Systematic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452767/
https://www.ncbi.nlm.nih.gov/pubmed/37636853
http://dx.doi.org/10.5005/jp-journals-10071-24511
work_keys_str_mv AT guptabhavna roleofnebulizedheparininclinicaloutcomeofcovid19patientswithrespiratorysymptomsasystematicreview
AT ahluwaliapallavi roleofnebulizedheparininclinicaloutcomeofcovid19patientswithrespiratorysymptomsasystematicreview
AT guptanidhi roleofnebulizedheparininclinicaloutcomeofcovid19patientswithrespiratorysymptomsasystematicreview
AT guptaanish roleofnebulizedheparininclinicaloutcomeofcovid19patientswithrespiratorysymptomsasystematicreview